Invention Grant
- Patent Title: Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
-
Application No.: US16068559Application Date: 2017-01-06
-
Publication No.: US10435388B2Publication Date: 2019-10-08
- Inventor: Yuntao Song , Alexander James Bridges
- Applicant: CS PHARMATECH LIMITED
- Applicant Address: KY Grand Cayman
- Assignee: CS Pharmatech Limited
- Current Assignee: CS Pharmatech Limited
- Current Assignee Address: KY Grand Cayman
- Agency: Cooley LLP
- International Application: PCT/US2017/012466 WO 20170106
- International Announcement: WO2017/120429 WO 20170713
- Main IPC: C07D403/04
- IPC: C07D403/04 ; C07D471/04 ; C08F20/58 ; C08F20/60 ; C07D401/14 ; C07D405/14 ; C07D401/04 ; C07D403/14 ; A61P35/00
Abstract:
The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
Public/Granted literature
- US20190023689A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE Public/Granted day:2019-01-24
Information query
